Hot Features
プレミアム
Immutep Ltd (IMMP)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. 詳細を表示
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable...
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first...
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s...
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients...
Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is...
Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcomaOver three-fold increase in...
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial designEfti...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Monksdream
4月前
Monksdream
6月前
Vector2112
6月前
glenn1919
6月前
Monksdream
6月前
Monksdream
8月前
Monksdream
1年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
The Night Stalker
2年前
DewDiligence
2年前
Invest-in-America
2年前
stocks2watch
3年前
make it happen
4年前
calahan67
4年前
make it happen
4年前
sgunderbarth
4年前
ClayTrader
4年前
make it happen
4年前
make it happen
4年前
make it happen
4年前
make it happen
4年前
reverse_long
4年前
calahan67
4年前
ClayTrader
4年前
DewDiligence
4年前
calahan67
4年前
calahan67
4年前
calahan67
4年前
everything
4年前
akamaii
4年前
lecorb
4年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
